Objective
Data for association between diabetes and SARS-CoV-2 susceptibility are conflicting. We aimed to evaluate this association using an analytical cross-sectional study design.
Methods
Study participants were recruited from endocrine clinics of our hospital and belonged to three groups: group 1 (T1DM), group 2 (T2DM), and group 3 (controls). All participants submitted blood samples for SARS-CoV-2 S1/S2 IgG antibody test (Diasorin Liaison), and were interviewed for history of documented infection.
Results
We evaluated total of 643 participants [T1DM: 149, T2DM: 160, Control: 334; mean age: 37.9±11.5 years]. A total of 324 (50.4%) participants were seropositive. Seropositivity rate was significantly higher in T1DM (55.7% vs. 44.9%, p=0.028) and T2DM (56.9% vs. 44.9%, p=0.013) groups, then control group. Antibody levels in seropositive T1DM and T2DM participants were not significantly different from seropositive controls. On multivariable analysis, low education status [OR: 1.41 (95% CI, 1.03, 1.94), p=0.035], diabetes [OR: 1.68 (95% CI, 1.20, 2.34), p=0.002], and overweight/obesity [OR: 1.52 (95% CI, 1.10, 2.10), p=0.012] showed significant association with SARS-CoV-2 seropositivity. The association between diabetes and SARS-CoV-2 seropositivity was found to further increase in participants with co-existing overweight/obesity [adjusted OR, 2.63 (95% CI, 1.54, 4.47, p<0.001].
Conclusions
SARS-CoV-2 seropositivity, assessed before the onset of national vaccination program, was significantly higher in participants with T1DM and T2DM, compared to controls. The antibody response did not differ between seropositive participants with and without diabetes. These findings point towards an increased SARS-CoV-2 susceptibility for patients with diabetes, in general, without any differential effect of the diabetes type.